Initiating oxcarbazepine, but not levetiracetam, linked to increased incidence rate ratio for nontrauma fracture
WEDNESDAY, Sept. 22, 2021 (HealthDay News) — For children aged 4 to 13 years with epilepsy, initiating oxcarbazepine, but not levetiracetam, antiseizure medication (ASM) is associated with an increased risk for nontrauma fracture, according to a study published in the September issue of Epilepsia.
Daniel G. Whitney, Ph.D., from the University of Michigan in Ann Arbor, and colleagues extracted claims data for children aged 4 to 13 years with at least five years of continuous health plan enrollment. Children with epilepsy who were ASM-naive were grouped according to treatment initiation, including levetiracetam or oxcarbazepine, and were compared to children without epilepsy and without ASM exposure. For up to four years of follow-up, the crude incidence rate (IR, per 1,000 person-years) and IR ratio (IRR) were estimated for nontrauma fracture.
The researchers found that the crude IR for nontrauma fracture was 21.5, 19.8, and 34.4 for non-ASM users without epilepsy, those taking levetiracetam, and those taking oxcarbazepine, respectively. The crude IRR of nontrauma fractures was similar for levetiracetam and non-ASM users (IRR, 0.92; 95 percent confidence interval, 0.63 to 1.34) and was elevated for oxcarbazepine (IRR, 1.60; 95 percent confidence interval, 1.09 to 2.35); compared with levetiracetam, the crude IRR was elevated for oxcarbazepine (IRR, 1.74; 95 percent confidence interval, 1.02 to 2.99). After adjustment for covariates, the findings were consistent, except for the comparison of oxcarbazepine with levetiracetam (hazard ratio, 1.71; 95 percent confidence interval, 0.99 to 2.93).
“Knowing that oxcarbazepine is associated with a higher fracture risk will allow clinicians to be more thoughtful about to which children they prescribe the medication,” a coauthor said in a statement.
Abstract/Full Text (subscription or payment may be required)
Characteristics of Individuals Diagnosed With Autism Have Changed Since 2010
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing
Polypharmacy of Prescription Medications Increased for U.S. Older Adults